Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.66 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268405 | 0.92 | CYP3A4 (0.57) | CYP3A4SLC7A5CPB2HRH4HRH3 | |
| SCHEMBL724387 | 0.90 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL27575969 | 0.88 | CYP3A4 (0.52) | CYP3A4SLC7A5CPB2HRH4HRH3 | |
| SCHEMBL6338597 | 0.87 | CYP3A4 (0.69) | CYP3A4SLC7A5CPB2HRH4HRH3 | |
| SCHEMBL21772061 | 0.87 | CYP3A4 (0.61) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL22462180 | 0.87 | CYP3A4 (0.60) | CYP3A4SLC7A5CPB2HRH4HRH3 | |
| SCHEMBL22462183 | 0.87 | CYP3A4 (0.60) | CYP3A4SLC7A5CPB2HRH4HRH3 | |
| SCHEMBL27819287 | 0.84 | CYP3A4 (0.57) | CYP3A4SLC7A5 | |
| SCHEMBL163444 | 0.84 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL1537285 | 0.84 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108795965-A | A kind of screening technique of polar amino acid superior strain | 北京理工大学 | 2018-11-13 | — | — | CN | claimed |
| EP-0210257-A4 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS. | HURWITZ CHARLES (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0210257-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ, Charles (US) | 1987-02-04 | — | — | EP | claimed |
| WO-1986004588-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ CHARLES (US) | 1986-08-14 | — | — | WO | claimed |
| EP-2070426-A2 | Improved Animal Feedstuff for Ruminants | The Glenside Group Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| CN-1826129-A | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS INC (US) | 2006-08-30 | — | — | CN | disclosed |
| CN-1197618-C | mutant cholera holotoxin adjuvant | AMERICAN CYANAMID CO (US) | 2005-04-20 | — | — | CN | disclosed |
| CN-1320043-A | mutant cholera holotoxin adjuvant | AMERICAN CYANAMID CO (US) | 2001-10-31 | — | — | CN | disclosed |
| EP-1117435-A1 | MUTANT CHOLERA HOLOTOXIN AS AN ADJUVANT | AMERICAN CYANAMID COMPANY (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018434-A1 | MUTANT CHOLERA HOLOTOXIN AS AN ADJUVANT | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0182579-B2 | METHOD FOR STABILIZING IMMOBILIZED FIBRINOLYTIC ENZYME | UNITIKA LTD. (JP) | 1992-08-26 | — | — | EP | disclosed |
| EP-0094116-A2 | Therapeutic granules | THE PROCTER & GAMBLE COMPANY (US) | 1983-11-16 | — | — | EP | disclosed |